103 results on '"Kukreti, Vishal"'
Search Results
2. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population
3. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
4. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
5. Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study
6. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience
7. A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score
8. Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience
9. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
10. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
11. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
12. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
13. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
14. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
15. Five hematologic tests and treatments to question
16. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
17. High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-Line Bendamustine Rituximab and Rituximab Maintenance
18. IBCL-550 High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
19. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
20. Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma
21. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
22. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
23. Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
24. Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
25. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
26. Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
27. Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
28. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
29. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study
30. 47 - Tandem Transplantation in Myeloma Patients with High Risk Cytogenetics: A 10 Year Single-Centre Experience
31. Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?
32. Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study
33. Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).
34. The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting
35. Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study
36. Evaluation of Unexplained Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnostic Clinic
37. Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience
38. Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma
39. Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review
40. Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments
41. A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation
42. Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant
43. Treatment Outcome of North American Patients with Adult T-Cell Leukemia/Lymphoma: Princess Margaret Cancer Centre Experience
44. Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience
45. Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience
46. Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience
47. Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma
48. Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis
49. Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre
50. Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.